Search

Connecting our employees to nonprofits that help people around the world

Learn about the new online tool that we’re using to help our employees connect with nonprofits that are providing critical services to communities, choose volunteer activities in their field, and lend their expertise to those in need.

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

Cleaning up the coast for a greener future

Employees from our Fremont site connect with nature and clean up the environment.

Clinical trials deliver medical breakthroughs – but how do they happen?

Clinical trials deliver medical breakthroughs – but how do they happen? Prof. Dr Martina Brueckmann talks about her role getting new drugs to trial.

Results announced from EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial in adults following a heart attack.

Our Partners: ViraTherapeutics

Boehringer Ingelheim announces InPedILD PhaseIII trial results

FDA Grants OFEV® (nintedanib) BTD for Chronic Fibrosing ILDs | Boehringer Ingelheim US

FDA grants Breakthrough Therapy Designation to OFEV for chronic fibrosing ILDs with a progressive phenotype. View ISI, PI and Med Guide.

Boehringer included on LinkedIn’s “Top Companies 2024” list

Investing in our people is at the core of what we do

SEMINTRA® (Telmisartan Oral Solution) | Boehringer Ingelheim US

Introducing SEMINTRA® (telmisartan oral solution) —The first FDA-approved liquid solution for the control of systemic feline hypertension.

Welcome to the Neuroscience Gallery | Boehringer Ingelheim US

Click here to take a guided tour through our Neuroscience virtual 3-D art exhibition, helping us to improve how we diagnose and treat various diseases.

US FDA grants Fast Track designation to Jardiance® (empagliflozin) to improve outcomes following a heart attack

The View from Both Sides of the Table

Pushing for Progress

Jardiance® (empagliflozin) Meets Endpoint Reducing CV Death | BI US

BI announces results from the EMPEROR-Reduced trial with heart failure with reduced ejection fraction, with & without diabetes. View ISI, PI and Med Guide.

Jardiance® (empagliflozin) Shows Reduction in CV Risk & Death | Boehringer Ingelheim US

BI & Eli Lilly & Co.’s JARDIANCE reduced risk of CV death, non-fatal heart attack or non-fatal stroke by 14%. View ISI, PI and Med Guide.

New Jardiance® findings showed improved cardio-renal outcomes in adults with heart failure with reduced ejection fraction regardless of chronic kidney disease status

Protecting Humans & Animals | COVID-19 | Boehringer Ingelheim US

Read more on Boehringer Ingelheim's commitment to protecting both humans and animals during the COVID-19 pandemic.

Data Show Safety of Pradaxa® (dabigatran etexilate) in Children | Boehringer Ingelheim US

BI announces results from 2 pediatric studies of PRADAXA, presented at the ISTH Congress in Melbourne. View ISI, PI and Med Guide.

BI Cares Financial Contributions Program

Full data announced in DINAMO trial in young people with T2D

Jardiance (empagliflozin) tablets is the first SGLT2 inhibitor to show statistically significant

What can the Patient do?

Mental Health and the Value of Connection

A grandmother’s empathy offers a safe space for people with mental health conditions

Supporting the Friendship Bench to improve access to mental healthcare.

The Research Process

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers